Phase 3 N=576 Gan & Lee Insulin Glargine Target Type (1) Evaluating Research
Diabetes Mellitus, Type 1
Primary: Treatment-induced Anti-Insulin Antibody (TI-AIA) — 4.8; 42.5 Titers
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=606 A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata
Alopecia Areata
Primary: Percentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤ 20 — 2.6; 17.3; 32.5 percentage of participants — p=<0.001
Phase 3 N=435 Follitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND)
Infertility, Female
Primary: Number of Oocytes Retrieved — 11.1; 9.6 Oocytes — p=0.0185
Phase 3 N=375 Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)
Atopic Dermatitis
Primary: Reduction of Worst Itch in Atopic Dermatitis — -3.6; -3.5 units on a scale
Phase 3 N=240 Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure at Week 4 — -6.2; -6.8 mmHg — p=0.0231
Phase 3 N=176 Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients
Nervous System Disease · Genetic Syndrome
Primary: Change From Baseline in Modified International Cooperative Ataxia Rating Scale (mICARS) — 0.8; 1.0; 2.3 score on a scale — p=0.0847
Phase 3 N=477 LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Heavy Menstrual Bleeding · Uterine Fibroid
Primary: Percentage Of Participants Who Achieved Or Maintained An MBL Volume Of <80 Milliliters (mL) And At Least A 50% Reduction From Baseline MBL Volume At Week 52/End Of…
Phase 3 N=3,506 Myocardial Ischemia and Transfusion
Myocardial Infarction · Anemia
Primary: Number of Participants With All-cause Mortality or Nonfatal Myocardial Reinfarction — 255; 295 Participants
Phase 3 N=298 A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial
Growth Hormone Deficiency, Pediatric · Endocrine System Diseases · Hormone Deficiency
Primary: Number of Subjects With Treatment-Emergent Adverse Events [Long-Term Safety and Tolerability] — 226 Participants
Phase 3 N=362 Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines
Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Primary: Main Period: Percentage of Glabellar Frown Line (GFL) Responders at Day 30 — 0; 52.3 percentage of subjects — p=<0.0001
Phase 3 N=220 Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida
Pre-Eclampsia · Hypertension in Pregnancy · Obesity
Primary: Number of Participants With Preeclampsia Diagnosis With Severe Features Based on Clinician Diagnosis — 37; 41 Participants
Phase 3 N=510 A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy
Cystic Fibrosis
Primary: Treatment Period: Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 504…
Phase 3 N=1,950 Stent vs. Indomethacin for Preventing Post-ERCP Pancreatitis
Post-ERCP Pancreatitis
Primary: The Proportion of Subjects in Each Study Group With Post-ERCP Pancreatitis — 145; 110; 137; 90 Participants
Phase 3 N=120 A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes
Cystic Fibrosis
Primary: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 118; 13 Participants
Phase 3 N=1,325 Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate Vaccine
Meningitis
Primary: Number of Participants With Seroprotection for Meningitis Serogroups A, C, W and Y — 373; 191; 366; 180 Participants